Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Study of Lorlatinib in ROS1 Rearranged NSCLC

NCT03612154 ·Status: UNKNOWN ·Phase: PHASE2

Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC

NCT06904547 ·Status: NOT_YET_RECRUITING

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

NCT04541706 ·Status: COMPLETED ·Phase: PHASE4

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

NCT07083687 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

NCT06092086 ·Status: RECRUITING ·Phase: PHASE2

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

NCT04621188 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

NCT06282874 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

NCT06361589 ·Status: RECRUITING

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Lorlatinib Continuation Study

NCT05144997 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

NCT06690541 ·Status: NOT_YET_RECRUITING

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

NCT02927340 ·Status: UNKNOWN ·Phase: PHASE2

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

NCT06876675 ·Status: ENROLLING_BY_INVITATION

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

NCT05167500 ·Status: COMPLETED

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

NCT06893354 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

NCT05631249 ·Status: RECRUITING ·Phase: PHASE2

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

NCT06858410 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

NCT04647110 ·Status: COMPLETED

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

NCT01685138 ·Status: COMPLETED ·Phase: PHASE2

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

NCT06652555 ·Status: NOT_YET_RECRUITING

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

NCT06678555 ·Status: ACTIVE_NOT_RECRUITING

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

NCT06247826 ·Status: RECRUITING ·Phase: NA

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

NCT05017025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

NCT04216121 ·Status: RECRUITING